Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.
Erişim
info:eu-repo/semantics/closedAccessTarih
2023Yazar
Özcan, MuhitLee, Seung Tae
Mensah, Felix
Modi, Dipenkumar
Fossa, Alexander
Kim, Won Seog
Paszkiewicz-Kozik, Ewa
Sevindik, Ömür Gökmen
Lavie, David
Üst veri
Tüm öğe kaydını gösterKünye
Özcan, M., Lee, S. T., Mensah, F., Modi, D., Fossa, A., Kim, W. S. ... Lavie, D. (2023). Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 41(16). Chicago, IL, 02-06 June, 2023.Özet
...